1. Yan G et al. Distinguishing Zika from Dengue in Singapore through Simple Clinical Assessment. Emerg Infect Dis. 2018 Aug;24(8):1565-1568. doi: 10.3201/eid2408.171883.
2. Yan G et al. Histoplasmosis presenting with Sweet’s syndrome. Clin Microbiol Infect. 2020 Jun;26(6)795-796. doi: 10.1016/j.cmi.2020.01.031
3. Yan G et al. Covert COVID-19 and false-positive dengue serology in Singapore. Lancet Infect Dis. 2020 May;20(5):536. doi: 10.1016/S1473-3099(20)30158-4
4. Tan SS, Saw S, Yan G et al. Limitations of rapid diagnostic testing in the work-up of dengue infection – a case report. Clin Chem Lab Med 2020. doi: 10.1515/cclm-2020-0288
5. Archuleta S, Cross G, Somani J, Lum L, Santosa A, Alagha RA, Allen DM, Ang A, Beh D, Chai L, Chan SM, Lim SM, Olszyna DP, Ong C, Oon J, Salada BMA, Smitasin N, Sun L, Tambyah PA, Tham SM, Yan G et al. Responding to COVID-19: how an academic infectious diseases division mobilized in Singapore. BMC Medicine. 2020 Jun 8; 18(1):179. doi: 10.1186/s12916-020-01641-7
6. Dickens BSL, Lim JT, Low JW, Lee CK, Sun YXH, Nasir HBM, Yan G et al. Simple ‘Rule-of-6’ Predicts Severe COVID-19 Disease. Clin Infect Dis. 2020 Jul 6; doi: 10.1093/cid/ciaa938
7. Tham SM, Lim WY, Lee CK, Loh J, Premkumar A, Yan B, Kee A, Chai L, Tambyah PA, Yan G. Four Patients with COVID-19 and Tuberculosis, Singapore, April-May 2020. Emerg Infect Dis. 2020 Nov;26(11):2764-2766. doi: 10.3201/eid2611.202752
8. Yan G et al. Relative bradycardia in patients with mild-to-moderate coronavirus disease, Japan. Emerg Infect Dis. 2021 Jan;27(1). doi: 10.3201/eid2701/203312
9. CK Lee, JWM Tham, S Png, CN Chai, SC Ng, EJM Tan, LJ Ng, RP Chua, M Sani, Y Seow, G Yan, J Tang. Clinical Performance of Roche cobas 6800, Luminex ARIES, MiRXES Fortitude Kit 2.1, altona RealStar, and Applied Biosystems TaqPath for SARS-CoV-2 Detection in Nasopharyngel Swabs. J Med Virol. 2021 Mar 14. doi: 1002/jmb.26940
10. Ooi KH, Liu MM, Tay JWD, Teo SY, Kaewsapsak P, Jin S, Lee CK, Hou J, Maurer-Stroh S, Lin W, Yan B, Yan G, Gao YG, Tan MH. An engineered CRISPR-Cas12a variant and DNA-RNA hybrid guides enable robust and rapid COVID-19 testing. Nat Commun 12, 1739 (2021). doi: 10.1038/s41467-021-21996-6